Tuesday, 22 May 2012 21:48

Nomura Quick Note: "Launches US Phase III trial for EPP treatment"

CLINUVEL Pharmaceuticals (CUV) has started its confirmatory Phase III US study of the novel drug afamelanotide, for the treatment of erythropoietic protoporphyria (EPP), a rare light intolerance disorder. The Phase III trial protocol has been designed in close consultation with the US Food and Drug Administration (FDA).